Haystack™ ctDNA Test for Lung Cancer Treatment Guidance
This study is looking at how a blood test called the Haystack™ ctDNA Assay can help doctors decide on the best treatment after surgery for people with Stage II-III non-small cell lung cancer (NSCLC). The test looks for tiny bits of cancer DNA in your blood to see if any cancer cells might still be present after surgery. Researchers want to see if using this test to guide treatments like radiation therapy, immunotherapy, or targeted therapy can improve how well patients do. You may be able to join if you are 18-90 years old, have Stage II-III NSCLC, and have recently had surgery for your lung cancer. The study aims to enroll 25 participants, but the current recruitment status is unclear.
- Study design
- This is a pilot, single-arm study, meaning all participants will receive the Haystack™ ctDNA Assay. It aims to enroll 25 participants.
- What's involved
- You will have blood samples taken at baseline, 2-4 weeks, 3 months, 6 months, and 12 months after surgery to detect circulating tumor DNA.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your circulating tumor DNA levels will be measured for up to 12 months after surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Detection of Circulating Tumor DNA (ctDNA) Post-SurgeryBaseline, 2-4 weeks, 3 months, 6 months, and 12 months post-surgery
This outcome will assess the presence or absence of circulating tumor DNA (ctDNA) in blood samples collected at multiple time points following surgical resection of Stage II-III non-small cell lung cancer (NSCLC). The Haystack™ ctDNA assay will be used to detect minimal residual disease (MRD), and results will be evaluated for their ability to predict recurrence and guide postoperative radiation and systemic therapy decisions.